smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Progressing a platform of small-molecule enzymatic activators that induce self-digestion of bacteria as novel mode of action against multi-drug resistant Gram-negative and Gram-positive bacteria Funding round led by Anobis Asset and Bayern Kapital; second closing remains open Munich, Germany, Oct. 22, 2025 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful first closing of its €4.7 M Pre-Series A financing round. The round was led by new investors Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators as well as existing investors HTGF – High-Tech Gründerfonds and Boehringer Ingelheim Venture Fund (BIVF). A second closing of the round remains open to investors. smartbax will use the funds to progress its proprietary pipeline of small-molecule antibiotics designed to overcome bacterial resistance with innovative approaches and novel me
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]Yahoo! Finance
- Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in DecemberPR Newswire
- Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
- Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form 8-K
- IMUX's page on the SEC website